Navigation Links
AMT Announces Presentations During the 11th Annual Meeting of the ASGT
Date:5/28/2008

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a series of presentations during the 11th Annual Meeting of the American Society of Gene Therapy in Boston, including a presentation on the pivotal clinical trial with its lead product AMT-011 on May 29.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... 2014 The ability for organizations to ... will allow individuals to perform at the highest of ... employers looking to compete in this post–recession era. ... trend, as the sector increasingly focuses on the importance ... will have real results on the organization's development and ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... 7 Medicsight PLC, a subsidiary,of MGT Capital ... industry leader in the,development of Computer-Aided Detection (CAD) ... received approval from the Brazilian regulatory,agency, Agencia Nacional ... David Sumner, Chief Executive of Medicsight, commented: "This ...
... DENVER, Aug. 7 Quest Product Development, ... a $1,000,000 Small Business,Technology Transfer grant by ... the development of a next-generation endoscope. MicroFlex,technology, ... alloys and,micro-actuators that allow active control over ...
... AutoImmune Inc. (OTC,Pink Sheets: AIMM) today reported a net ... the three months ended June 30, 2008, compared with,a net ... diluted, for the,three months ended June 30, 2007. For the ... or $0.01 per share basic and diluted, compared,with net loss ...
Cached Biology Technology:Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 2Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software 3NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
(Date:8/28/2014)... identified the developmental on-off switch for Streptomyces , ... two-thirds of the world,s naturally derived antibiotic medicines. ... it is possible to manipulate this switch to make ... appearing August 28 in Cell , found that ... and a larger protein called BldD ultimately controls whether ...
(Date:8/28/2014)... good examples of complex systems. Their infrastructure equipment ... for cooling, transport to supply fuel, and ICT ... the network chain is interconnected with a wider ... team of UK-based scientists has studied various aspects ... have been published in EPJ B by Gaihua ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Inter-dependent networks stress test 2
... computer-based text-searching tool developed by UT Southwestern Medical Center ... in a database for similarities, providing a more efficient ... offering scientific journal editors a new tool to thwart ... efficient at flagging publications that are highly similar, said ...
... automated sensors may soon help NOAA scientists better predict ... ice will melt, and whether soggy Pacific storms will ... of NOAAs Unmanned Aircraft Systems program. NOAA recently ... use of the crewless vehicles for wide-ranging research designed ...
... of this message: , About the Ocean Sciences ... Book Hotel Rooms by 4 February 2008 Abstracts and ... Ocean Sciences Meeting , This years meeting will offer ... and Earths water wherever it is found, from mountain ...
Cached Biology News:Computer-based tool aids research, helps thwart questionable publication practices 2Computer-based tool aids research, helps thwart questionable publication practices 3NOAA invests $3 million for unmanned aircraft system testing 2Media advisory -- 2008 Ocean Sciences Meeting 2Media advisory -- 2008 Ocean Sciences Meeting 3Media advisory -- 2008 Ocean Sciences Meeting 4
... Reagent B - Permeabilisation medium LEUCOPERM ... suspension with Reagent A and then permeabilising ... gives antibodies access to intracellular structures and ... cells intact. Specific formulations reduce background staining ...
... Rabbit polyclonal to JNK1 (phospho T183 + Y185) ... internal domain containing phosphorylated T183/Y185. Reactivity / ... Not yet tested in other species. Background ... including the ERK, JNK, and p38 kinases. The ...
... Dako Target Retrieval Solution, pH 9 ... Tris/EDTA buffer, pH 9, intended for heat-induced ... It is well-suited for use on formalin-fixed, ... Compared with 0.01 mol/L citrate buffer, pH ...
... has been designed to provide a thin film-like barrier ... a slide. This barrier creates the proper surface ... area on the slide. PAP Pen contains a ... It can be removed, if desired, by xylene ...
Biology Products: